Principal Investigator
Gerald Soff
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20260096
Clinical Trial Summary
Statin Therapy to Prevent Cancer Associated Venous Thromboembolism:
A randomized, double-blind, placebo-controlled trial of rosuvastatin 20 mg po daily in the prevention of venous thromboembolism (VTE) and other cardiovascular events among individuals recently diagnosed with cancer who are not scheduled to receive prophylactic anticoagulation and are at risk for VTE as defined by a Khorana Score (KS) 2 to 4 or a modified Khorana Score (mKS) 2 to 5
Phase
Phase IV
Funding Agency/Sponsor
Externally Peer-Reviewed
Disease
Classical Hematology
Contact Information
Phone Number
305-243-2647